Total Payments
$191,504
2024 Payments
$468.89
Companies
48
Transactions
291
Medicare Patients
3,425
Medicare Billing
$285,360
Payment Breakdown by Category
Research$186,129 (97.2%)
Food & Beverage$4,149 (2.2%)
Travel$1,225 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $186,129 | 31 | 97.2% |
| Food and Beverage | $4,149 | 256 | 2.2% |
| Travel and Lodging | $1,225 | 4 | 0.6% |
Payments by Type
Research
$186,129
31 transactions
General
$5,374
260 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $154,858 | 15 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $15,373 | 16 | $0 (2021) |
| Allergan Inc. | $9,410 | 8 | $0 (2019) |
| Shire North American Group Inc | $6,331 | 6 | $0 (2019) |
| Eli Lilly and Company | $1,722 | 1 | $0 (2022) |
| Astellas Pharma US Inc | $328.24 | 20 | $0 (2024) |
| Amgen Inc. | $283.23 | 19 | $0 (2024) |
| PFIZER INC. | $276.28 | 17 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $259.42 | 19 | $0 (2023) |
| Lilly USA, LLC | $237.06 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $468.89 | 25 | Otsuka America Pharmaceutical, Inc. ($100.77) |
| 2023 | $714.10 | 44 | Bayer Healthcare Pharmaceuticals Inc. ($106.78) |
| 2022 | $2,415 | 47 | Eli Lilly and Company ($1,722) |
| 2021 | $9,878 | 31 | Takeda Pharmaceuticals U.S.A., Inc. ($9,458) |
| 2020 | $6,407 | 46 | Takeda Pharmaceuticals U.S.A., Inc. ($5,915) |
| 2019 | $69,120 | 62 | Gilead Sciences, Inc. ($58,981) |
| 2018 | $98,854 | 24 | Gilead Sciences, Inc. ($92,360) |
| 2017 | $3,646 | 12 | Gilead Sciences Inc ($3,517) |
All Payment Transactions
291 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/21/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: Diabetes Care | ||||||
| 06/24/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: Diabetes | ||||||
| 06/07/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: Obesity | ||||||
| 05/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: DIABETES | ||||||
| 05/13/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Diabetes | ||||||
| 05/09/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: Pulmonology | ||||||
| 05/08/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: Diabetes | ||||||
| 04/25/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.34 | General |
| Category: PSYCHIATRY | ||||||
| 04/11/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: Inflammation | ||||||
| 04/10/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: CARDIOVASCULAR | ||||||
| 03/28/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE, SYNJARDY | Food and Beverage | In-kind items and services | $22.19 | General |
| Category: DIABETES | ||||||
| 03/27/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: Respiratory | ||||||
| 03/25/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: Iron Deficiency Anemia | ||||||
| 03/21/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: Biological | ||||||
| 03/18/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $26.27 | General |
| Category: UROLOGY | ||||||
| 03/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $15.29 | General |
| 03/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $22.19 | General |
| Category: PSYCHIATRY | ||||||
| 03/06/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/27/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: PSYCHIATRY | ||||||
| 02/22/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: UROLOGY | ||||||
| 02/07/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Respiratory | ||||||
| 02/06/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: Biological | ||||||
| 01/16/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $26.58 | General |
| Category: PSYCHIATRY | ||||||
| 01/16/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: PSYCHIATRY | ||||||
| 01/08/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $13.94 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease | Gilead Sciences, Inc. | $77,554 | 4 |
| Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Ulcerative Colitis | Gilead Sciences, Inc. | $69,563 | 8 |
| A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis | Allergan Inc. | $7,424 | 1 |
| A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (FIGARO UC 301) | Takeda Pharmaceuticals U.S.A., Inc. | $5,458 | 2 |
| A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS FIGARO UC 301 | Shire North American Group Inc | $5,400 | 3 |
| A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (AIDA) | Takeda Pharmaceuticals U.S.A., Inc. | $4,412 | 1 |
| A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Ulcerative Colitis | Gilead Sciences, Inc. | $4,224 | 1 |
| EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN PARTICIPANTS WITH MODERATE TO SEVERE CROHN'S DISEASE | Takeda Pharmaceuticals U.S.A., Inc. | $4,000 | 2 |
| A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease | Gilead Sciences, Inc. | $3,500 | 1 |
| A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | Allergan Inc. | $1,972 | 6 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $1,722 | 1 |
| A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS AIDA | Shire North American Group Inc | $899.22 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 607 | 756 | $107,131 | $49,823 |
| 2022 | 15 | 943 | 1,129 | $154,030 | $77,511 |
| 2021 | 14 | 919 | 1,206 | $152,479 | $80,221 |
| 2020 | 14 | 956 | 1,267 | $145,800 | $77,805 |
Total Patients
3,425
Total Services
4,358
Medicare Billing
$285,360
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 86 | 179 | $31,325 | $15,574 | 49.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 87 | 87 | $19,140 | $10,663 | 55.7% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 47 | 47 | $14,570 | $7,660 | 52.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 73 | 110 | $15,950 | $5,972 | 37.4% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 59 | 60 | $12,000 | $3,364 | 28.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 30 | 30 | $3,000 | $2,269 | 75.6% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 29 | 32 | $4,000 | $1,563 | 39.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 32 | 32 | $1,280 | $938.56 | 73.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 61 | 62 | $3,596 | $554.76 | 15.4% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2023 | 12 | 12 | $600.00 | $486.60 | 81.1% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 20 | 20 | $600.00 | $346.80 | 57.8% |
| 81002 | Urinalysis, manual test | Office | 2023 | 60 | 74 | $740.00 | $252.34 | 34.1% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 11 | 11 | $330.00 | $178.42 | 54.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 92 | 203 | $35,525 | $17,307 | 48.7% |
| 99483 | Assessment of and care planning for impaired thought processing, typically 50 minutes | Office | 2022 | 80 | 80 | $24,800 | $14,363 | 57.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 100 | 100 | $22,000 | $12,536 | 57.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 66 | 103 | $14,935 | $6,575 | 44.0% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2022 | 102 | 106 | $21,200 | $6,301 | 29.7% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 20 | 20 | $6,000 | $5,572 | 92.9% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 71 | 71 | $7,100 | $4,988 | 70.3% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 64 | 67 | $8,375 | $4,302 | 51.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 79 | 79 | $3,160 | $2,204 | 69.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 100 | 105 | $6,090 | $994.43 | 16.3% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 26 | 27 | $1,080 | $755.69 | 70.0% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2022 | 18 | 18 | $900.00 | $734.48 | 81.6% |
About Dr. Val Hansen, M.D
Dr. Val Hansen, M.D is a Internal Medicine healthcare provider based in Bountiful, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235224296.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Val Hansen, M.D has received a total of $191,504 in payments from pharmaceutical and medical device companies, with $468.89 received in 2024. These payments were reported across 291 transactions from 48 companies. The most common payment nature is "" ($186,129).
As a Medicare-enrolled provider, Hansen has provided services to 3,425 Medicare beneficiaries, totaling 4,358 services with total Medicare billing of $285,360. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Bountiful, UT
- Active Since 10/04/2006
- Last Updated 08/09/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1235224296
Products in Payments
- Vascepa (Drug) $216.00
- ELIQUIS (Drug) $184.52
- MYRBETRIQ (Drug) $174.98
- ENTRESTO (Drug) $168.12
- REXULTI (Drug) $146.27
- TRADJENTA (Drug) $142.13
- Kerendia (Drug) $118.95
- GEMTESA (Drug) $111.50
- Veozah (Drug) $110.12
- Otezla (Drug) $104.61
- XARELTO (Drug) $103.82
- LEQVIO (Drug) $91.30
- TRULICITY (Drug) $80.88
- SPRAVATO (Drug) $80.27
- TOUJEO (Drug) $72.92
- Prolia (Biological) $70.46
- JARDIANCE (Drug) $70.24
- FARXIGA (Drug) $65.75
- MOUNJARO (Drug) $64.95
- Aimovig (Biological) $64.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Bountiful
Dr. Joshua Oaks, M.d, M.D
Internal Medicine — Payments: $14,892
Internal Medicine $14,892
Dr. Lisani Estopinan, M.d, M.D
Internal Medicine — Payments: $6,878
Internal Medicine $6,878
Dr. Joseph Jensen, Md, MD
Internal Medicine — Payments: $4,402
Internal Medicine $4,402
Bryan Bartholomew, Do, DO
Internal Medicine — Payments: $238.67
Internal Medicine $238.67
Dr. Tyler Bickel, M.d, M.D
Internal Medicine — Payments: $228.15
Internal Medicine $228.15
Dr. Nedda Hendler, Md, MD
Internal Medicine — Payments: $209.63
Internal Medicine $209.63